Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and Diagnostics.

doi:10.1093/ajcp/aqab164

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and Diagnostics.

American journal of clinical pathology - 1 Apr 2022

Pfeifer John D, Loberg Robert, Lofton-Day Catherine, Zehnbauer Barbara A

Abstract excerpt

OBJECTIVES: Diversity of laboratory-developed tests (LDTs) using next-generation sequencing (NGS) raises concerns about their accuracy for selection of targeted therapies. A working group developed a pilot study of traceable reference samples to measure NGS LDT performance among a cohort of clinical laboratories. METHODS: Human cell lines were engineered via CRISPR/Cas9 and prepared as formalin-fixed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to High-Throughput Nucleotide Sequencing
Share to Mutation
Share to Pilot Projects

Source

Open in PubMed

Identifiers

PMID: 34871357
DOI: 10.1093/ajcp/aqab164

Provenance

PubMed metadata and Literature Corpus relationships.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics